Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Int J Androl ; 32(6): 675-86, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19515174

RESUMO

We evaluated the potential for growth and intrauterine development of embryos generated from the fertilization of oocytes with spermatozoa recovered from animals with chronic renal failure (CRF). Group A included sham-operated rats (n = 28), group B1 involved CRF rats that had undergone erythropoietin plus bromocryptine treatment (n = 28), and group B2 included CRF rats that had received normal saline. Embryos derived from the in vitro fertilization of oocytes with spermatozoa recovered from rats of group A or group B1 or group B2 were transferred to female recipients. We induced CRF in a group of rats (group B; n = 56; the total kidney volume was reduced to one-sixth with two operations). One week after the second operation, the rats of group B were randomly divided into group B1 (they subsequently received bromocryptine plus erythropoietin) and group B2 (they received injections of saline). Nine weeks after the second operation, the fertility of each male rat was assessed by mating tests and in vitro fertilization of oocytes. The mean litter size was significantly smaller in the subpopulation of fertile animals in group B2 than in the fertile rats of group B1 and in the fertile rats of group B1 than in the fertile rats of group A. Per cent of transferred blastocysts that developed into alive offspring were significantly lower in group B2 than in group B1 and in group B1 than in group A. Epididymal spermatozoa demonstrated a significantly larger DNA-oxidative damage in group B2 than in group B1 and in group B1 than in group A. These findings demonstrate that sperm-DNA damage because of CRF development is accompanied by a defect in the development of embryos generated in vitro. We may suggest that bromocryptine and erythropoietin protecting sperm DNA from oxidative damage improve reproductive potential in rats with CRF.


Assuntos
Eritropoetina/farmacologia , Fertilização/fisiologia , Falência Renal Crônica/fisiopatologia , Oócitos/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Animais , Epididimo , Feminino , Fertilidade , Fertilização in vitro , Rim/patologia , Masculino , Ratos , Ratos Wistar
2.
J Steroid Biochem Mol Biol ; 109(3-5): 323-30, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18400489

RESUMO

Normal testicular function is dependent upon hormones acting through endocrine and paracrine pathways both in vivo and in vitro. Sertoli cells provide factors necessary for the successful progression of spermatogonia into spermatozoa. Sertoli cells have receptors for follicle stimulating hormone (FSH) and testosterone which are the main hormonal regulators of spermatogenesis. Hormones such as testosterone, FSH and luteinizing hormone (LH) are known to influence the germ cell fate. Their removal induces germ cell apoptosis. Proteins of the Bcl-2 family provide one signaling pathway which appears to be essential for male germ cell homeostasis. In addition to paracrine signals, germ cells also depend upon signals derived from Sertoli by direct membrane contact. Somatostatin is a regulatory peptide playing a role in the regulation of the proliferation of the male gametes. Activin A, follistatin and FSH play a role in germ cell maturation during the period when gonocytes resume mitosis to form the spermatogonial stem cells and differentiating germ cell populations. In vitro cultures systems have provided evidence that spermatogonia in advance stage of differentiation have specific regulatory mechanisms that control their fate. This review article provides an overview of the literature concerning the hormonal pathways regulating spermatogenesis.


Assuntos
Hormônios/metabolismo , Mitose , Espermatogênese , Espermatozoides/citologia , Espermatozoides/metabolismo , Animais , Células Germinativas/citologia , Humanos , Masculino , Células de Sertoli/citologia , Células de Sertoli/metabolismo
3.
Asian J Androl ; 8(6): 643-73, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17111067

RESUMO

Pregnancies achieved by assisted reproduction technologies, particularly by intracytoplasmic sperm injection (ICSI) procedures, are susceptible to genetic risks inherent to the male population treated with ICSI and additional risks inherent to this innovative procedure. The documented, as well as the theoretical, risks are discussed in the present review study. These risks mainly represent that consequences of the genetic abnormalities underlying male subfertility (or infertility) and might become stimulators for the development of novel approaches and applications in the treatment of infertility. In addition, risks with a polygenic background appearing at birth as congenital anomalies and other theoretical or stochastic risks are discussed. Recent data suggest that assisted reproductive technology might also affect epigenetic characteristics of the male gamete, the female gamete, or might have an impact on early embryogenesis. It might be also associated with an increased risk for genomic imprinting abnormalities.


Assuntos
Epigênese Genética , Infertilidade Masculina/genética , Injeções de Esperma Intracitoplásmicas/efeitos adversos , Animais , Pré-Escolar , Aberrações Cromossômicas , Deleção Cromossômica , Anormalidades Congênitas/genética , Feminino , Impressão Genômica , Infecções por HIV/transmissão , Haploidia , Humanos , Lactente , Transmissão Vertical de Doenças Infecciosas , Síndrome de Klinefelter/genética , Masculino , Gravidez , Diagnóstico Pré-Implantação , Risco , Aberrações dos Cromossomos Sexuais , Espermatogênese/genética , Translocação Genética/genética , Cromossomo X/genética , Cariótipo XYY/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA